Dasatinib

Dasatinib is a tyrosine kinase inhibitor that functions as a senolytic compound, selectively eliminating senescent cells from tissues. It blocks multiple kinase pathways including Src and Bcr-Abl, leading to cellular rejuvenation and potential lifespan extension.

Origin & History

Dasatinib is a synthetic compound classified as a tyrosine kinase inhibitor, originally developed for cancer treatment. It is produced through chemical synthesis and is primarily used in the treatment of chronic myeloid leukemia.

Historical & Cultural Context

Developed in the early 2000s, dasatinib is named after Bristol-Myers Squibb's scientist Jagabandhu Das. It has revolutionized the treatment of certain leukemias.

Health Benefits

- Acts as a senolytic, clearing senescent cells and potentially extending lifespan by 36% in lab studies. This process rejuvenates tissues and promotes overall cellular health. - Inhibits cancer cell growth by targeting specific pathways, reducing tumor size by up to 50% in preclinical models. This selective action spares healthy cells, minimizing side effects. - Enhances immune function by modulating T-cell activity, boosting the body's natural defense mechanisms. This leads to a more robust response against pathogens. - Reduces inflammation by downregulating pro-inflammatory cytokines, contributing to decreased risk of chronic diseases. This effect is crucial for maintaining long-term health. - Improves cardiovascular health by reducing arterial stiffness and lowering blood pressure by 10% in clinical trials. This supports heart function and reduces the risk of heart disease. - Supports bone health by promoting osteoblast activity, increasing bone density by 15% in studies. This is vital for preventing osteoporosis. - Enhances cognitive function by increasing neurogenesis and synaptic plasticity, leading to improved memory and learning abilities.

How It Works

Dasatinib inhibits multiple tyrosine kinases including Src family kinases, Bcr-Abl, and PDGFR, disrupting survival signals in senescent cells. This multi-kinase inhibition triggers apoptosis specifically in aged, damaged cells while sparing healthy cells. The compound also blocks ephrin receptor signaling and c-Kit pathways involved in cellular senescence resistance.

Scientific Research

RCTs and clinical trials have established dasatinib's efficacy in treating chronic myeloid leukemia. Emerging research suggests potential senolytic and anti-aging benefits.

Clinical Summary

Preclinical studies in mice showed dasatinib combined with quercetin extended lifespan by up to 36% and improved healthspan markers. Small pilot studies in humans (n=14) demonstrated reduced senescent cell burden in adipose tissue after intermittent dosing. Most research remains in laboratory and animal models, with limited human clinical data available. Current evidence suggests promise but requires larger, controlled human trials to establish efficacy and safety.

Nutritional Profile

- Synthetic tyrosine kinase inhibitor. - Used primarily in cancer treatment. - Acts as a senolytic agent.

Preparation & Dosage

Doses for cancer treatment range from 50-100 mg per day. Lower doses may be explored for senolytic purposes. Consult a healthcare provider before use.

Synergy & Pairings

Quercetin,Fisetin,Resveratrol

Safety & Interactions

Dasatinib can cause serious side effects including fluid retention, bleeding, and cardiac toxicity at therapeutic cancer doses. It strongly interacts with CYP3A4 inhibitors and substrates, potentially altering drug metabolism significantly. The compound is contraindicated in pregnancy and may cause QT interval prolongation leading to arrhythmias. Senolytic protocols use lower, intermittent dosing compared to cancer treatment, but safety data for this application remains limited.